4/29/2014 9:30:16 AM
MENLO PARK, Calif., April 29, 2014 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc., (Nasdaq:PACB) and HistoGenetics, a global leader in Human Leukocyte Antigen (HLA) sequence-based typing (SBT), announced today that HistoGenetics has selected the PacBio DNA Sequencing platform for its unique ability to sequence full-length HLA genes and to provide fully phased HLA alleles. HistoGenetics has purchased two PacBio RS II DNA Sequencing systems, which will be used for HLA typing and will be evaluated as potential replacements for Sanger sequencing.
Help employers find you! Check out all the jobs and post your resume.
comments powered by